The primary purpose of this study is to evaluate the efficacy and safety of X-396
(ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that
have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
1. Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage
IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is
ALK-positive by an FDA-approved assay performed centrally. Patients must be ALK
positive by local test prior to submitting tissue to the central lab. Randomization
will occur after ALK positive confirmation is received from the central lab. Patients
may have received up to 1 prior chemotherapy regimen for metastatic disease, which may
also include maintenance therapy. Note that patients that have received adjuvant or
neoadjuvant chemotherapy and developed metastatic disease within 6 months from the end
of that therapy would be considered to have received 1 prior regimen for metastatic
2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.
(see Appendix A)
3. Life expectancy of at least 12 weeks.
4. Ability to swallow and retain oral medication.
5. Adequate organ system function, defined as follows:
1. Absolute neutrophil count (ANC) ≥1.5 x 109/L
2. Platelets ≥100 x 109/L
3. Hemoglobin ≥9 g/dL (≥90 g/L) Note that transfusions are allowed to meet the
required hemoglobin level
4. Total bilirubin ≤1.5 times the upper limit of normal (ULN)
5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN if
no liver involvement or ≤5 x ULN with liver involvement.
6. Creatinine < 1.5 x ULN. If >1.5 x ULN, patient may still be eligible if
calculated creatinine clearance >50 mL/min (0.83mL/s) as calculated by the
6. Brain metastases allowed if asymptomatic at study baseline. Patients with untreated
brain metastases must not be on corticosteroids. If patients have neurological
symptoms or signs due to CNS metastases, patients need to complete whole brain
radiation or focal treatment at least 14 days before start of study treatment and be
asymptomatic on stable or decreasing doses of corticosteroids at baseline.
7. Men with partners of childbearing potential willing to use adequate contraceptive
measures during the study and for 90 days after the last dose of study medication.
8. Women who are not of child-bearing potential, and women of child-bearing potential who
agree to use adequate contraceptive measures during the study and for 90 days after
the last dose of study medication, and who have a negative serum or urine pregnancy
test within 1 week prior to initial trial treatment.
9. Patients must be >18 years-of-age.
10. Patients must have measurable disease per RECIST v. 1.1.
11. Willingness and ability to comply with the trial and follow-up procedures.
12. Ability to understand the nature of this trial and give written informed consent.
Note the following pertains to patients enrolled in France
In France, a subject will be eligible for inclusion in this study only affiliated to the
French Social Security system, and currently benefit from the corresponding rights and
1. Patients that have previously received an ALK TKI or PD-1/PD-L1 therapy, and patients
currently receiving cancer therapy (i.e., other targeted therapies, chemotherapy,
radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or
2. Use of an investigational drug within 21 days prior to the first dose of study drug.
Note that to be eligible, any drug-related toxicity should have recovered to Grade 1
or less, with the exception of alopecia.
3. Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14
4. Patients with primary CNS tumors and leptomeningeal disease are ineligible.
5. Patients with a previous malignancy within the past 3 years (other than curatively
treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any
cancer that is considered to be cured and have no impact on PFS and OS for the current
6. Concomitant systemic use of anticancer herbal medications. These should be stopped
prior to study entry.
7. Patients receiving
1. strong CYP3A inhibitors (including, but not limited to, atazanavir,
clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,
ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit,
2. strong CYP3A inducers (including, but not limited to, carbamazepine,
phenobarbital, phenytoin, rifabutin, rifampin, St. John's Wort)
3. CYP3A substrates with narrow therapeutic window (including, but not limited to,
alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,
quinidine, sirolimus, tacrolimus).
8. Women who are pregnant or breastfeeding.
9. Presence of active gastrointestinal (GI) disease or other condition that will
interfere significantly with the absorption, distribution, metabolism, or excretion of
10. Patients at risk for GI perforation.
11. Clinically significant cardiovascular disease including:
1. QTcF interval >450 ms for men and >470 ms for women, symptomatic bradycardia <45
beats per minute or other significant ECG abnormalities in the investigator's
2. Clinically uncontrolled hypertension in the investigator's opinion (e.g., blood
pressure >160/100 mmHg; note that isolated elevated readings considered to not be
indicative of uncontrolled hypertension are allowed).
The following within 6 months prior to Cycle 1 Day 1:
1. Congestive heart failure (New York Heart Class III or IV).
2. Arrhythmia or conduction abnormality requiring medication. Note: patients with
atrial fibrillation/flutter controlled by medication and arrhythmias controlled
by pacemakers are eligible.
3. Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial
4. Cerebrovascular accident or transient ischemia.
12. Patients who are immunosuppressed (including known HIV infection), have a serious
active infection at the time of treatment, have interstitial lung disease/pneumonitis,
or have any serious underlying medical condition that would impair the ability of the
patient to receive protocol treatment. Patients with controlled hepatitis C, in the
investigator's opinion, are allowed. Patients with known hepatitis B must be HBeAg and
HB viral DNA negative for enrollment. Note that, because of the high prevalence, all
patients in the Asia-Pacific region (except Australia, New Zealand, and Japan) must be
tested and, if HBsAg positive, must be HBeAg and HB viral DNA negative for enrollment.
13. Known hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule.
14. Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol.
15. Concurrent condition that in the investigator's opinion would jeopardize compliance
with the protocol or would impart excessive risk associated with study participation
that would make it inappropriate for the patient to be enrolled.
16. Inability or unwillingness to comply with study and/or follow-up procedures outlined
in the protocol.
Note the following pertains to patients enrolled in France
17. In France, a subject will not be eligible when under legal protection.